Ocrelizumab and liver injury research information (PubMed) on: November 04, 2019, 02:43:44 pm #1 The Overview section of the report on Ocrevus that is part of a larger report entitled LiverTox: Clinical and Research Information on Drug-Induced Liver Injury, issued by the National Institute of Diabetes and Digestive and Kidney Diseases. This section was last updated in July 2018. Ocrelizumab Ocrelizumab is a humanized monoclonal antibody to CD20 which is used as therapy of multiple sclerosis. Ocrelizumab is associated with a low rate serum enzyme elevations during therapy and to rare i... NCBI Bookshelf · ncbi.nlm.nih.gov The "likelihood score" for Ocrevus is E*, which is defined as:QuoteCategory E*. The drug is suspected to be capable of causing liver injury or idiosyncratic acute liver injury but there have been no convincing cases in the medical literature. In some situations cases of acute liver injury have been reported to regulatory agencies or mentioned in large clinical studies of the drug, but the specifics and details supportive of causality assessment are not available. The agent is unproven, but suspected to cause liver injury. Last Edit: November 04, 2019, 02:54:00 pm by agate Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
